# Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

> **NCT01942135** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 521 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT01942135
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-26
- **Primary completion:** 2014-12-05
- **Final completion:** 2022-09-28
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2024-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942135, "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01942135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*